| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Pharmaceuticals (Health Care sector), AKBA's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 3.72M | $2.34M | - | |
| VP | 948.4K | $1.32M | - | |
| CFO | 616.6K | $684.4K | - | |
| VP | 588.4K | $817.8K | - | |
| Other | 561.8K | $780.8K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2018 | Nash Duane | Director | Sell | 1,000 | $14.62 | $14,620.00 | -4.4% | |
| Oct 2, 2017 | Nash Duane | Director | Sell | 1,188 | $19.64 | $23,332.32 | -5.0% | |
| Oct 2, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 7,803 | $19.89 | $155,188.42 | -7.1% | |
| Oct 2, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,398 | $19.64 | $27,456.72 | -1.4% | |
| Sep 28, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 5,000 | $19.30 | $96,500.00 | -4.9% | |
| Aug 15, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 5,000 | $15.00 | $75,000.00 | -4.7% | |
| Jul 5, 2017 | Satter Muneer A58 | Director | Buy | 1,034,482 | $14.50 | $14,999,989.00 | +51.7% | |
| Jul 3, 2017 | Dahan Michel59 | SVP, Chief Business Officer | Sell | 1,399 | $14.26 | $19,946.52 | -1.3% | |
| Jul 3, 2017 | Hadas Nicole R.60 | SVP, General Counsel, Sec. | Sell | 1,554 | $14.26 | $22,156.47 | -1.4% | |
| Jul 3, 2017 | Nash Duane | Director | Sell | 990 | $14.27 | $14,127.30 | -4.0% |